



## Programme scientifique préliminaire de la CCRC virtuelle de 2021

Toutes les heures sont indiquées en heure de l'Est.

<b>Lundi 8 novembre 2021</b>				
12 h à 12 h 15	<b>Mots de bienvenue et d'ouverture</b>			
12 h 15 à 13 h 45	<b>Séance principale et table ronde – Personnalisation des mégadonnées</b>			
13 h 45 à 14 h	<b>Pause</b>			
14 h à 14 h 15	<b>LS -1A - Séance et discussion éclair – Soins palliatifs</b>	<b>ORAL 1A - Séance parallèle avec questions et réponses – Microenvironnement tumoral et immunologie</b>	<b>ORAL 1B - Séance parallèle avec questions et réponses – Approches des essais cliniques sur le cancer</b>	<b>Séminaire - Recherche menée par les Autochtones et gouvernance des données dans la lutte contre le cancer</b>
14 h 15 à 14 h 30				
14 h 30 à 14 h 45				
14 h 45 à 15 h	<b>LS 1B - Séance et discussion éclair – Services et politiques de santé</b>			
15 h à 15 h 15	<b>Pause</b>			
15 h 15 à 15 h 30	<b>LS 1C - Séance et discussion éclair – Cancer du sang</b>	<b>ORAL 1C - Séance parallèle avec questions et réponses – Immunothérapie</b>	<b>ORAL 1D - Séance parallèle avec questions et réponses – Recherche sur le cancer chez les Autochtones</b>	
15 h 30 à 15 h 45				
15 h 45 à 16 h	<b>LS 1D - Séance et discussion éclair – Cancer du pancréas</b>			
16 h à 16 h 15				
16 h 15 à 16 h 30	<b>Synthèse de fin de journée</b>			

<b>Mardi 9 novembre</b>					
12 h à 12 h 15	<b>Mots de bienvenue et d'ouverture</b>				
12 h 15 à 13 h 45	<b>Séance principale et table ronde – Bien vieillir avec le cancer</b>				
13 h 45 à 14 h	<b>Pause</b>				
14 h à 14 h 15	<b>LS 2A - Séance et discussion éclair – Cancer du sein</b>	<b>LS 2B - Séance et discussion éclair – Cancer du cerveau</b>	<b>ORAL 2A - Séance parallèle avec questions et réponses – Médecine de précision et biomarqueurs</b>	<b>ORAL 2B - Séance parallèle avec questions et réponses – Résultats rapportés par les patients et expérience des patients</b>	<b>Séminaire - Recherche éthique auprès des Premières Nations, des Inuits et des Métis</b>
14 h 15 à 14 h 30					
14 h 30 à 14 h 45	<b>LS 2C - Séance et discussion éclair – Cancer colorectal</b>	<b>LS 2D - Séance et discussion éclair – Cancer du poumon</b>			
14 h 45 à 15 h					
15 h à 15 h 15	<b>Pause</b>				
15 h 15 à 15 h 30	<b>LS 2E -Séance et discussion éclair – Cancer pédiatrique</b>	<b>LS 2F - Séance et discussion éclair – Cancers rares</b>	<b>ORAL 2C - Séance parallèle avec questions et réponses – Métastases</b>	<b>Séance parallèle – Plateformes de recherche sur le cancer</b>	
15 h 30 à 15 h 45					
15 h 45 à 16 h	<b>LS 2G - Séance et discussion éclair – Cancer de la prostate</b>	<b>LS 2H - Séance et discussion éclair – Cancer de l'ovaire</b>			
16 h à 16 h 15					
16 h 15 à 16 h 30	<b>Synthèse de fin de journée</b>				

<b>Mercredi 10 novembre</b>				
12 h à 12 h 15	<b>Mots de bienvenue et d'ouverture</b>			
12 h 15 à 12 h 30	<b>LS 3A - Séance et discussion éclair –</b> Létalité synthétique	<b>ORAL 3A - Séance parallèle avec questions et réponses –</b> COVID-19 et le dépistage et le traitement du cancer	<b>ORAL 3B - Séance parallèle avec questions et réponses –</b> Mode de vie et régime alimentaire	
12 h 30 à 12 h 45				
12 h 45 à 13 h	<b>LS 3B - Séance et discussion éclair –</b> Métastases hépatiques			
13 h à 13 h 15				
13 h 15 à 13 h 30	<b>Pause</b>			
13 h 30 à 15 h	<b>Séance principale et table ronde –</b> Les traitements anticancéreux de demain aujourd'hui			
15 h à 15 h 15	<b>Pause</b>			
15 h 15 à 15 h 30	<b>LS 3C - Séance et discussion éclair –</b> Bio-informatique et génomique	<b>ORAL 3C - Séance parallèle avec questions et réponses –</b> Métabolisme	<b>ORAL 3D - Séance parallèle avec questions et réponses –</b> L'équité dans les soins en cancérologie	
15 h 30 à 15 h 45				
15 h 45 à 16 h	<b>LS 3D - Séance et discussion éclair –</b> Dommages et réparation de l'ADN			
16 h à 16 h 15				
16 h 15 à 16 h 30	<b>Synthèse de fin de journée</b>			

<b>Jeudi 11 novembre</b>				
12 h à 12 h 15	<b>Mots de bienvenue et d'ouverture</b>			
12 h 15 à 12 h 30	<b>LS 4A - Séance et discussion éclair – Chimiorésistance</b>	<b>ORAL 4A - Séance parallèle avec questions et réponses – Épigénétique</b>	<b>ORAL 4B - Séance parallèle avec questions et réponses – Imagerie et radio-oncologie</b>	
12 h 30 à 12 h 45				
12 h 45 à 13 h	<b>LS 4B - Séance et discussion éclair – Oncologie gériatrique</b>			
13 h à 13 h 15				
13 h 15 à 13 h 30	<b>Pause</b>			
13 h 30 à 13 h 45	<b>LS 4C - Séance et discussion éclair – Prévention</b>	<b>ORAL 4C - Séance parallèle avec questions et réponses – Mobilisation des patients</b>	<b>ORAL 4D - Séance parallèle avec questions et réponses – Bio-informatique et intelligence artificielle (IA)</b>	
13 h 45 à 14 h				
14 h à 14 h 15	<b>LS 4D - Séance et discussion éclair – Risque de cancer et prévention primaire</b>			
14 h 15 à 14 h 30				
14 h 30 à 14 h 45	<b>Pause</b>			
14 h 45 à 16 h 15	<b>Séance principale et table ronde – Comprendre et gérer les risques – La saga du cancer héréditaire</b>			
16 h 15 à 16 h 30	<b>Synthèse de la CCRC de 2021</b>			



## Lundi 8 novembre 2021

12 h à 12 h 15

Mots de bienvenue et d'ouverture

12 h 15 à 13 h 45

Séance principale et table ronde – Personnalisation des mégadonnées

Moderators:

Dr. Claudia Kleinman  
*McGill University, Lady Davis Institute*

Dr. Don Desserud  
*Patient Partner*

**Dawn of Digital Pathology: Leveraging AI for Cancer Biomarker Discovery**

Dr. Ali Bashashati  
*University of British Columbia, Vancouver Coastal Health Research Institute*

**Using Big Data to advance Precision Medicine in Oncology: Opportunities and Challenges**

Dr. Hermann Nabi  
*Social and Preventive Medicine, Université Laval*

**PROFYLE: The Canadian Pediatric Precision Oncology Initiative**

Dr. Rebecca Deyell  
*Pediatrics, University of British Columbia*

13 h 45 à 14 h

Pause

14 h à 15 h

ORAL 1A - Séance parallèle avec questions et réponses – Microenvironnement tumoral et immunologie

Chairs:

Dr. Paola Marcato  
*Dalhousie University, Beatrice Hunter  
Cancer Research Institute*

Mrs. Heather Hogan  
*Patient Partner*

**Investigating Intra-Tumour Metabolic Heterogeneity in Triple-Negative Breast Cancer**

Marina Fukano  
*McGill University*

**Harnessing synthetic lethality to drive ferroptosis in hypoxic solid tumours**

Dr. Shawn Chafe  
*BC Cancer Research Institute*

**Cancer cell plasticity leads to the activation of progenitor-like signaling pathways and immune checkpoint genes**

Dr. Iacovos Michael  
*Sunnybrook Research Institute*



## ORAL 1B - Séance parallèle avec questions et réponses – Approches des essais cliniques sur le cancer

### Chairs:

Dr. Madeline Li  
*University Health Network, Princess  
Margaret Cancer Centre*

Ms. Nathalie Baudais  
*Patient Partner*

**The Rethinking Clinical Trials (REaCT) program: leading pragmatic, practice-changing, patient-centred research across Canada**

Dr. Mark Clemons  
*Ottawa Hospital*

**PAROLE-Onco, accompanying patients as members of the care team: mirage or reality?**

Dr. Marie-Pascale Pomey  
*Centre de recherche du CHUM*

**Protocol for implementing a national exercise oncology program: Project EXCEL**

Dr. S. Nicole Culos-Reed  
*University of Calgary*

## Séminaire - Recherche menée par les Autochtones et gouvernance des données dans la lutte contre le cancer

### Facilitator:

Melissa Cernigoy  
*Canadian Partnership Against Cancer*

Indigenous-led research and data governance in cancer control is an emerging area of science that requires specialized knowledge and expertise. For example, current gaps in Indigenous cancer research and data systems exist within Canada while little exploration has been done to summarize existing promising practices in Indigenous cancer control data and research. In response, the Canadian Partnership Against Cancer is working with the an Indigenous Team, including the Alberta First Nations Information Governance Centre to undertake an environmental scan and engage relevant stakeholders on a regional, national and international scale. The project is designed to address the following aims:

1. To inform the implementation of the CPAC 2022-2027 Business Plan to be responsive to new and existing partner needs and aligning actions with the health system for FNIM governed research and data systems
2. To synthesize and integrate the key findings of the environmental scan engagement components for people-specific Indigenous governed research data systems and promising practices in cancer control data and research

This presentation will meet the following 3 objectives:

1. Provide an overview of the project, including guiding questions and primary activities
2. Present key findings from the environmental scan of published literature, Indigenous-led research, and relevant organizational reports, documents and frameworks
3. Discuss a holistic Indigenous model developed for data and information synthesis and interpretation grounded in Indigenous knowledge and conceptualizations of heart, spirit and mind

Dr. Angeline Letendre  
*Canadian Indigenous Nurses Association, Alberta Health Services*

Ms. Lea Bill  
*Canadian Indigenous Nurses Association*



14 h à 14 h 30

LS -1A - Séance et discussion éclair – Soins palliatifs

**The PROVIEW+ tool: Validating a cancer model to predict risk of death, poor performance status and severe symptoms over time**

Dr. Hsien Seow  
*McMaster University*

**Using stakeholder engagement to inform Canadian Cancer Society's position statement on medical assistance in dying (MAiD)**

Ms. Ruhi Kiflen  
*Canadian Cancer Society*

**Acceptability of Automatic Referrals to Supportive and Palliative Care by Patients Living with Advanced Lung Cancer: A Co-Design Process**

Dr. Aliyah Pabani  
*University of Calgary*

**Does early palliative care reduce end-of-life healthcare costs: A population-based, propensity-score matched cohort study**

Dr. Hsien Seow  
*McMaster University*

**Palliative home care and emergency department visits in the last 30 and 90 days of life: a retrospective cohort study of cancer patients**

Ms. Jennifer Mracek  
*University of Calgary*

14 h 30 à 15 h

LS 1B - Séance et discussion éclair – Services et politiques de santé

**The Use of Risk-Sharing Agreements to Reimburse High-Cost Oncology Drugs: Legal, Regulatory and Policy Considerations**

Melanie McPhail  
*Simon Fraser University*

**Lung cancer care in Saskatchewan and Ontario: An interprovincial analysis of patient characteristics and survival outcomes**

Mr. Dmitry Neymark  
*University of Saskatchewan*

**Preliminary evaluation results of the integrated knowledge translation approach utilized in the Canadian Population Attributable Risk of Cancer (ComPARE) study**

Apiramy Jeyapalan  
*Canadian Cancer Society*

**The use of complementary medicine among individuals with cancer: Standardizing assessment and documentation and evaluating prevalence and associations of use**

Dr. Lynda Balneaves  
*University of Manitoba*

**Characterizing the financial burden of advanced cancer: interim analysis of financial effects data from people living with advanced colorectal cancer**

Dr. Marc Kerba  
*University of Calgary*

15 h à 15 h 15

Pause



15 h 15 à 16 h 15

**ORAL 1C - Séance parallèle avec questions et réponses – Immunothérapie**

**Chairs:**

Dr. Shashi Gujar  
*Dalhousie University*

Ms. Chantale Thurston  
*Patient Partner*

**The spatial immune landscape of cutaneous melanoma**

Dr. Ian Watson  
*Goodman Cancer Research Centre, McGill University*

**Targeting CXCR2-mediated neutrophil recruitment to non-small cell lung cancer**

Mr. Simon Milette  
*McGill University*

**Elucidating the Role of the non-Receptor Tyrosine Kinase Fes in Tumour Immune Evasion**

Mr. Brian Laight  
*Queen's University*

**ORAL 1D - Séance parallèle avec questions et réponses – Recherche sur le cancer chez les Autochtones**

Dr. Brenda Elias  
*University of Manitoba*

Ms. Louise Bird  
*Patient Partner*

**Re-conceptualizing Metrics for an Indigenous Cancer Indicator Framework on Cancer Screening to Early Diagnosis and through the Cancer Journey**

Dr. Angeline Letendre  
*Canadian Indigenous Nurses Association*

**Exploring the cancer experiences and outcomes for Metis patients and families in Saskatchewan**

Mr. Adel Panahi and Miss Tegan Brock  
*Metis Nation - Saskatchewan*

**The Manitoba Metis Cancer Journey**

Ms. Julianne Sanguins  
*Manitoba Metis Federation*

15 h 15 à 15 h 45

**LS 1C - Séance et discussion éclair – Cancer du sang**

**Transient receptor potential vanilloid type calcium channel (TRPV6) as a novel therapeutic target in lymphoid tumours**

Dr. Alli Murugesan  
*University of New Brunswick*

**Molecular Subtyping of NPM1 mutated AML**

Dr. Arvind Mer  
*Princess Margaret Cancer Centre*

**Defining the biological significance and role of somatic TMEM30A mutations in diffuse large B cell lymphoma.**

Shannon Healy  
*BC Cancer Agency*

**A modular activatable synthetic biology system to visualize in vivo cell-cell communication**

Mr. TianDuo Wang  
*Robarts Research Institute*

**Mathematical modelling of perturbed hematopoiesis during the pre-leukemic phase of AML to evaluate therapeutic strategies for clonal reduction**

Mia Brunetti  
*Université de Montréal*





15 h 45 à 16 h 15

LS 1D - Séance et discussion éclair – Cancer du pancréas

**Exploring the effects of SBRT on the pancreatic tumor microenvironment using intravital fluorescence microscopy**

Mr. Timothy Samuel  
*University Health Network*

**TANDEM: Biomicrofluidic Systems with Transverse And Normal Diffusional Environments for Multidirectional Signalling**

Mr. Michael Mohan  
*University of Toronto*

**The Role of Neutrophil Extracellular Trap/CCDC25/Integrin Linked Kinase in Pancreatic Ductal Adenocarcinoma (PDAC) Progression and Metastasis**

Dr. Paul McDonald  
*BC Cancer Research Institute*

16 h 15 à 16 h 30

Synthèse de fin de journée

## Mardi 9 novembre

12 h à 12 h 15

Mots de bienvenue et d'ouverture

12 h 15 à 13 h 45

Séance principale et table ronde – Bien vieillir avec le cancer

Moderators:

Dr. Martine Puts  
*University of Toronto*

Ms. Debi Lascelle  
*Patient and Family Representative*

**Telomeres in Cancer and Aging**

Dr. Ronald DePinho  
*MD Anderson Cancer Center*

**Aging well during and after cancer therapies**

Dr. Shabbir Alibhai  
*Medicine, University Health Network*

**Working with older adults as they manage cancer: Evidence & opportunities**

Dr. Kristen Haase  
*School of Nursing, University of British Columbia*

**Dignity and Personhood in the Terminally Ill**

Dr. Harvey Chochinov  
*University of Manitoba*

13 h 45 à 14 h

Pause



14 h à 15 h

## ORAL 2A - Séance parallèle avec questions et réponses – Médecine de précision et biomarqueurs

### Chairs:

Dr. Elena Kuzmin  
*Concordia University, McGill University*

Dr. Christine Wu  
*Patient Partner*

### From cell signaling to drug targeting in melanoma

Dr. Ian Watson  
*Goodman Cancer Research Centre, McGill University*

### Deciphering intra-tumoral heterogeneity in multiple myeloma: A single cell study

Dr. Ali Mahdipour Shirayeh  
*University of Toronto*

### The receptor for hyaluronan-mediated motility as a regulator of drug sensitivity in triple-negative breast cancer

Ms. Britney Messam  
*Western University*

## ORAL 2B - Séance parallèle avec questions et réponses – Résultats rapportés par les patients et expérience des patients

### Chairs:

Dr. Lynn Gauthier  
*Research-Centre of the CHU de Québec,  
Cancer Research Centre, Université Laval*

Ms. Donna Pepin  
*Patient Partner*

### Harnessing the Power of Integrated Patient Reported Outcomes (PROs): Exploring the Relationship Between Symptom Complexity and Health System Utilization

Dr. Linda Watson  
*Alberta Health Services*

### Cancer Journey Experiences of Métis Albertans

Ms. June Kima  
*The Métis Nation of Alberta*

### Experiences and Perceptions of Older Adults with Lower-risk Hormone Receptor-positive Breast Cancer about Adjuvant Radiotherapy and Endocrine Therapy: A Patient Survey

Dr. Marie-France Savard  
*University of Ottawa*

## Séminaire - Recherche éthique auprès des Premières Nations, des Inuits et des Métis

### Facilitator:

Dr. Sara Urowtiz  
*Canadian Cancer Research Alliance, Canadian Partnership Against Cancer*

Sponsored by:



Join this “fireside chat” to gain a better understanding about how researchers and Indigenous community leaders engage in health/cancer-related research that is ethical and benefits First Nations, Inuit and Métis. Three panelists will share their thoughts, experiences and opinions on how they have built ethical research partnerships, included diverse perspectives in their research and are guided by First Nations, Inuit and Métis research principles and protocols.

Mr. Adel Panahi  
*Métis Nation – Saskatchewan*

Dr. Gary Groot  
*University of Saskatchewan*

Dr. Jennifer Shea  
*Memorial University*



14 h à 14 h 30

LS 2A - Lightning Session and Discussion - Breast Cancer

**Emergence of B1 integrin-deficient mammary tumors from dormancy involves both epithelial cell intrinsic and extrinsic mechanisms**

Miss Yu Gu  
*McGill University*

**Developing a model of HER2+/ER+ breast cancer to examine the role of the immune microenvironment on therapeutic response**

Miss Hailey Dall-Proud  
*McGill University*

**Inhibiting the adaptor protein ezrin enhances adaptive anti-tumor immune responses in a mouse model of triple-negative breast cancer**

Dr. Victoria Hoskin  
*Queen's University*

**Using Machine Learning to Identify Risk Factors for Severe Vasomotor Symptoms in Breast Cancer Patients**

Dr. Katherine Cole  
*University of Ottawa*

**Dissecting novel ShcA-regulated signalling networks that promote breast cancer progression and therapeutic resistance.**

Miss Kathryn Hunt  
*McGill University*

LS 2B - Séance et discussion éclair – Cancer du cerveau

**Regulation of mRNA translation by eIF5B in glioblastoma**

Dr. Nehal Thakor  
*University of Lethbridge*

**Invasive growth of brain metastases is driven by cancer cell-pSTAT3+ reactive astrocyte crosstalk**

Ms. Sarah Maritan  
*McGill University*

**Cell Cycle Regulation as a Permissive Early Event During Gliomagenesis**

Dr. Lisa Porter  
*University of Windsor*

**Glioblastoma Temozolomide Chemoresistance: Is Autophagy Playing a Role?**

Miss Courtney Clark  
*University of Manitoba*

**The Role of RNA Methyltransferase NSUN5 in Translational Reprogramming and Tumorigenesis in Glioblastoma**

Yan Shu Kong  
*University of Alberta*

14 h 30 à 15 h

LS 2C - Séance et discussion éclair – Cancer colorectal

**A systematic review of colorectal cancer prevention and screening interventions among Indigenous populations in Canada and abroad**

Ms. Eleeyah Uri  
*Ontario Health*

**Evaluation of algorithms using administrative health and structured electronic medical record data to determine breast and colorectal cancer recurrence in a Canadian province**

Mr. Pascal Lambert  
*CancerCare Manitoba*

**Treatment patterns and survival outcomes of early age-at-onset colorectal cancer patients in Alberta: a population-based study**

Dr. Dylan O'Sullivan  
*University of Calgary*



**Genomic instability and DNA damage regulate STING activation through characteristic cytosolic DNA structures in colorectal cancer**

Shayla Mosley  
*University of Alberta*

**Analyzing tumour infiltrating lymphocyte populations in MSI vs. MSS primary colon cancer patients using digital cytometry**

Ms. Sara Pietropaolo  
*Dalhousie University*

## LS 2D - Séance et discussion éclair – Cancer du poumon Cancer

**Création et caractérisation d'une cohorte provinciale de patients atteints d'un cancer du poumon à l'aide de données clinico-administratives**

Mr. Gino Boily  
*Institut d'excellence en santé et en services sociaux*

**Examining the Relationship Between Green Space, Air Pollution, and Lung Cancer Incidence Using Bayesian Hierarchical Modelling.**

Mr. Jonathan Simkin  
*BC Cancer*

**Perspectives of family physicians towards access to lung cancer screening for individuals living with low income**

Dr. Ambreen Sayani  
*Women's College Hospital*

**Infrared Spectroscopic Analysis of Exhaled Breath for Prediction of Progression-Free and Overall Survival in Lung Cancer Patients**

Ms. Erin Brooks  
*Dalhousie University*

**Non-small cell lung cancer survival by immigrant status: A population-based retrospective cohort study in Ontario, Canada**

Dr. Geetanjali Datta  
*Cedars-Sinai Medical Centre*

15 h à 15 h 15

Pause

15 h 15 à 16 h 15

## ORAL 2C - Séance parallèle avec questions et réponses – Métastases

Chairs:

Dr. Amina Zoubeidi  
*University of British Columbia*

Ms. Cathie Hays  
*Patient Partner*

**3D Chromatin Remodeling Potentiates Transcriptional Programs Driving Cell Invasion**

Dr. Michael Witcher  
*The Lady Davis Institute of McGill University*

**Proteomic screens for suppressors of anoikis identify IL1RAP as a promising surface target in Ewing sarcoma**

Dr. Haifeng Zhang  
*University of British Columbia*

**Neutrophil oxidative stress mediates obesity-associated vascular inflammation and metastatic transmigration**

Sheri McDowell  
*McGill University*



## Séance parallèle – Plateformes de recherche sur le cancer

### Chairs:

Ms. Kimberly Badovinac  
*Canadian Cancer Research Alliance, Canadian Partnership Against Cancer*

**The Canadian Tissue Repository Network CTRNet; update on biospecimen and data resources and tools to help cancer researchers**

Dr. Anne-Marie Mes-Masson  
*Centre de recherche du CHUM*

Dr. Peter Watson  
*BC Cancer*

**CanPath: A national platform for health research**

Dr. Trevor Dummer  
*University of British Columbia*

**Networked Support for Canada's Academic Cancer Trial Environment**

Mr. Stephen Sundquist  
*3CTN - Canadian Cancer Clinical Trials Network*

**Marathon of Hope Cancer Centres Network and Digital Health and Discovery Platform**

Mr. Stephen Herst  
*Terry Fox Research Institute*

Dr. Bryce Pickard  
*Digital Health and Discovery Platform*

15 h 15 à 15 h 45

## LS 2E - Séance et discussion éclair – Cancer pédiatrique

**Hearing Loss in Cisplatin-Treated Childhood Cancer Patients is Mediated by Toll-Like Receptor 4**

Ms. Asna Latif  
*University of Alberta*

**Potential pro-leukemic signaling through Toll-like receptor 3 in pediatric acute lymphoblastic leukemia**

Ms. Tanmaya Atre  
*BC Children's Hospital Research Institute*

**Understanding and preventing acute lymphoblastic leukemia late adverse effects using genomics and machine learning**

Mr. Nicolas Raymond  
*Université de Sherbrooke*

**Genetic and Transcriptional analysis of Patient-Derived Xenografts (PDXes) for Leptomeningeal Disease**

Miss Ana Isabel Castillo Orozco  
*McGill University, RI-MUHC*

## LS 2F - Séance et discussion éclair – Cancers rares

**STING Activation in Sarcoma: Assessing Clinically Relevant Therapeutic Strategies**

Ms. Karys Hildebrand  
*University of Calgary*

**Development of targeted radioimmunotherapy for osteosarcoma using comparative oncology approach**

Mr. Chandra Bose Prabakaran  
*University of Saskatchewan*

**Characterization of metabolic rewiring and identification of potential therapeutic targets in CBFA2T3-GLIS2-dependent AMKL**

Dr. Caroline Capdevielle  
*Centre de recherche HMR*

**Tumorigenic properties of uveal melanoma cancer cells grown in 3D or on a reconstructed extracellular matrix**

Oliver Chancy  
*Université Laval*



**Alterations on intracellular localization and trafficking of the RET receptor induced by Multiple Endocrine Neoplasia type 2 mutations**

Mr. Eduardo Reyes-Alvarez  
*Queen's University*

**15 h 45 à 16 h 15**

**LS 2G - Séance et discussion éclair – Cancer de la prostate**

**Clinical and genomic indolence in lung recurrent metastatic hormone-sensitive prostate cancer**

Dr. Nicolette Fonseca  
*University of British Columbia*

**Identifying Circulating Genes to Stratify Patients with Advanced Prostate Cancer and Predict Therapeutic Response**

Miss Seta Derderian  
*RI-MUHC*

**Identification of Cellular Signatures Predictive of Human Prostate Cancer Progression**

Ms. Chloe Liu  
*McGill University, Goodman Cancer Research Centre*

**The role of receptor tyrosine kinase ROR2 in stemness and immune evasion**

Ms. Nakisa Tabrizian  
*University of British Columbia / Vancouver Prostate Centre*

**The gut microbiome-prostate tumour crosstalk is modulated by dietary polyunsaturated fatty acids**

Mr. Jalal Laaraj  
*Centre de recherche du CHU de Québec-Université Laval*

**LS 2H - Séance et discussion éclair – Cancer de l'ovaire**

**Targeting NAD metabolism counters PARP inhibitor resistance in ovarian cancer**

Mr. Alex Sauriol  
*Institut du cancer de Montreal*

**Cystathionine gamma lyase: A promising therapeutic target in clear cell carcinoma of the ovary**

Dr. Amal EL-Naggar  
*University of British Columbia*

**Development of theranostic probes against MUC16 to enable PET/CT imaging for early detection and targeted radioimmunotherapy of MUC16 expressing ovarian cancers.**

Miss Hanan Babeker  
*University of Saskatchewan*

**Oviduct epithelial cells constitute two developmentally distinct lineages that are spatially separated along the distal-proximal axis**

Dr. Matthew Ford  
*McGill University, Goodman Cancer Research Centre*

**Developing an ovarian cancer tissue cell fate (TCFate) manipulation and detection tool**

Miss Marie Orléan ADA NDONG  
*Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM)*

**16 h 15 à 16 h 30**

**Synthèse de fin de journée**



## Mercredi 10 novembre

12 h à 12 h 15

Mots de bienvenue et d'ouverture

12 h 15 à 13 h 15

### ORAL 3A - Séance parallèle avec questions et réponses – COVID-19 et le dépistage et le traitement du cancer

Chairs:

Dr. Timothy Hanna  
*Queen's University*

Ms. Melissa Coombs  
*Patient Partner*

**Predicted impact of the COVID-19 pandemic on cancer incidence and mortality in Canada**

Dr. Talía Malagón  
*McGill University*

**Utilization of COVID-19 related funding modifications for systemic cancer therapies in Ontario, Canada**

Ms. Jaclyn Beca  
*Ontario Health*

**Evaluating the impact of the COVID-19 pandemic on new cancer diagnoses and oncology care in Manitoba**

Dr. Kathleen Decker  
*CancerCare Manitoba, University of Manitoba*

### ORAL 3B - Séance parallèle avec questions et réponses – Mode de vie et régime alimentaire

Chairs:

Dr. P. Peter Wang  
*University of Toronto*

Mr. Archie Stewart  
*Patient Partner*

**Psychiatric Disorder Incidence Among Adolescents and Young Adults Aged 15-39 with Cancer: A Population-Based Cohort Study**

Dr. Miranda Fidler-Benaoudia  
*University of Calgary*

**The Association of Estimated Cardiorespiratory Fitness and Overweight and Obesity with Invasive Breast Cancer: A prospective cohort study**

Miss Rebecca Christensen  
*University of Toronto*

**Investigating the relationship between heavy metal exposure and cancer risk in Canada**

Miss Katherine Pullella  
*University of Toronto*

12 h 15 à 12 h 45

### LS 3A - Séance et discussion éclair – Létalité synthétique

**Preclinical Studies on Novel Treatment Plans for Metastatic Triple Negative Breast Cancers**

Dr. Armin Gamper  
*University of Alberta, Cross Cancer Institute*

**Genome-Wide CRISPR Cas9 Screen Reveals a Synthetic Lethal Interaction Between PARG and PTEN in Melanoma**

Mr. Emmanuel Asante  
*McGill University*

**Genome-wide CRISPR Screens Identify Ferroptosis as a Novel Therapeutic Vulnerability in Acute Lymphoblastic Leukemia**

Dr. Marie-Eve Lalonde  
*National Research Council*



**The roles of 4E-BP1 in breast cancer metastasis**

Mr. Predrag Jovanovic  
*Lady Davis Institute*

**Characterizing the role of ETFDH on cancer biology**

Dr. David Papadopoli  
*Lady Davis Institute*

**12 h 45 à 13 h 15**

### LS 3B - Séance et discussion éclair – Métastases hépatiques

**The role of Estrogen in the Immune Microenvironment of Liver Metastases**

Miss Yasmine Benslimane  
*McGill University*

**Immunoprofiling the Impact of Treatments on Co-opting Histological Growth Patterns of Colorectal Cancer Liver Metastases**

Diane Kim  
*McGill University Health Centre*

**EV derived Proteomics profile to stratify Angiogenic and Non-Angiogenic HGPS in Colorectal Cancer Liver metastasis**

Mrs. Migmar Tsamchoe  
*Research Institute of McGill University Health Centre*

**A comprehensive analysis of SNPs and CNVs in relation to survival outcomes in colorectal cancer**

Mr. Yajun Yu  
*Memorial University of Newfoundland*

**1 h 15 à 1 h 30**

Pause

**13 h 30 à 15 h**

### Séance principale et table ronde – Les traitements anticancéreux de demain aujourd'hui

**Moderators:**

Dr. Madhuri Koti  
*Queen's University*

Ms. Ruth Ackerman  
*Patient and Family Representative*

**Single-cell sequencing for identifying lung cancer biomarkers**

Dr. Paola Marignani  
*Biochemistry and Molecular Biology, Dalhousie University*

**Clinical Applications of Liquid Biopsy in Oncology**

Dr. Lilian Siu  
*University Health Network*

**From the Clinic to the Lab: Investigating Mechanisms of Response and Resistance to Immune Checkpoint Therapy**

Dr. Padmanee Sharma  
*MD Anderson Cancer Centre*





13 h 15 à 13 h 30

Pause

15 h 15 à 16 h 15

### ORAL 3C - Séance parallèle avec questions et réponses – Métabolisme

Chairs:

Dr. Rachel Murphy  
*University of British Columbia*

Mr. Angus Pratt  
*Patient Partner*

**Mevalonate metabolism as an actionable vulnerability of t(4;14)-positive multiple myeloma**

Dr. Joseph Longo  
*Van Andel Institute*

**Metabolic adaptations supporting the evolution of resistance to chemotherapeutics in breast cancer**

Mr. Yannick Audet-Delage  
*University of Ottawa*

**Targeting metabolism as a novel therapeutic strategy to suppress oncogenic MYC in group 3 medulloblastoma tumors**

Emma Martell  
*University of Manitoba*

### ORAL 3D - Séance parallèle avec questions et réponses – L'équité dans les soins en oncologie

Chairs:

Dr. Erin Strumpf  
*McGill University*

Ms. Mei-Lin Yee  
*Patient Partner*

**Building on Existing Tools to Improve Chronic Disease Prevention and Screening in Public Health: A Cluster Randomized Trial**

Dr. Aisha Lofters  
*Women's College Hospital*

**Exploring Health Equity in a Context of Cancer Prevention from Alberta Métis Perspectives**

Dr. Angeline Letendre  
*Canadian Indigenous Nurses Association*

**High prevalence of triple negative and quadruple negative breast cancer among women of African ancestry compared to Caucasian women**

Shawn Hercules  
*McMaster University*

15 h 15 à 15 h 45

### LS 3C - Séance et discussion éclair – Bio-informatique et génomique

**Circulating-tumour DNA Derived Nucleosome Positioning Captures Tissue Gene Expression And Transcription Factor Activity In Prostate Cancer**

Ms. Xinyi Chen  
*Vancouver Prostate Centre*

**In-silico selection of potential overexpressed cancer protein markers in blood plasma samples**

Dr. Huiyan Li  
*University of Guelph*



**Application of Generalized Multifactor Dimensionality Reduction (GMDR) methods to identify potential multi-SNP interactions associated with survival times in colorectal cancer patients**

Mr. Aaron Curtis  
*Memorial University of Newfoundland*

**Orchestrating and sharing large multimodal biomedical data for more transparent and reproducible biomarker discovery**

Dr. Benjamin Haibe-Kains  
*University Health Network*

**LDCT Lung Sub-cm Nodule Malignancy Prediction with Combination Radiomics and Machine Learning Models**

Mr. Ian Janzen  
*BC Cancer*

15 h 45 à 16 h 15

### LS 3D - Séance et discussion éclair – Dommages et réparation de l'ADN

**Investigation of the sexual dimorphic tumor suppressor role of DDX3X in melanoma**

Mrs. Marine Lingrand  
*McGill University*

**High sensitivity of p53 mutated sonic hedgehog medulloblastoma to ATM inhibition**

Mrs. Niusha Khazaei  
*McGill University*

**The role of HORMAD1 in DNA damage repair in squamous cell carcinomas**

Mrs. Jennifer Gantchev  
*McGill University*

**Revival Stem Cells Mediate P53-Dependent DNA Repair to Regenerate the Intestinal Epithelium**

Dr. Arshad Ayyaz  
*Mount Sinai Hospital*

**Beyond BRCA1 during DNA repair by homologous recombination (HR): characterization of the zinc finger protein POGZ as a novel pro-HR factor**

Dr. Alexandre Orthwein  
*Lady Davis Institute*

16 h 15 à 16 h 30

Synthèse de fin de journée

## Jeudi 11 novembre

12 h à 12 h 15

Mots de bienvenue et d'ouverture



12 h 15 à 13 h 15

#### ORAL 4A - Séance parallèle avec questions et réponses – Épigénétique

**Chairs:**

Dr. Gareth Williams  
*University of Calgary*

Dr. Rosilene Kraft  
*Patient Partner*

**MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets**

Dr. David Labbé  
*McGill University*

**Uncovering the dosage-dependent roles of Arid1a in gastric tumorigenesis for combinatorial drug therapy**

Mr. Adrian Loe  
*Hospital for Sick Children*

**Systematic characterization of the bromodomain containing subunits within the mSWI/SNF chromatin remodeling complexes**

Miss Lynda AGBO  
*Université Laval*

#### ORAL 4B - Séance parallèle avec questions et réponses – Imagerie et radio-oncologie

**Chairs:**

Dr. Nawaid Usmani  
*University of Alberta*

Ms. Katey Thompson  
*Patient Partner*

**Predicting Prostate Cancer Response to Brachytherapy Using AI Driven Digital Pathology**

Dr. Calum MacAulay  
*BC Cancer*

**Ionizing radiation upregulates TKS5 expression in Glioblastoma**

Ms. Lisa Decotret  
*BC Cancer*

**Anti-hypertensive Drug Modulates Cancer-Associated Fibroblasts to Improve Radiation Response**

Ms. Che-Min Lee  
*BC Cancer Research Centre*

12 h 15 à 12 h 45

#### LS 4A - Séance et discussion éclair – Chimiorésistance

**Overcoming cancer recurrence and metastatic progression by targeting anastasis**

Dr. Wells Brown  
*British Columbia Cancer Research Institute*

**Identify Targetable Molecular Drivers of Chemotherapy Resistance in Gastro-Esophageal Adenocarcinoma**

Ms. Iris Kong  
*McGill University*

**SMARCA4/2 loss inhibits chemotherapy-induced apoptosis by restricting IP3R3-mediated Ca<sup>2+</sup> flux to mitochondria**

Miss Kangning Yang  
*McGill University*

**Reciprocal metabolic and epigenetic adaptations to microenvironment stress exposes vulnerabilities in breast cancer**

Ms. Geneviève Deblois  
*Université de Montréal*

**Immune checkpoint inhibitor resistance mutations in the IFN-JAK-STAT pathway increase melanoma sensitivity to oncolytic virus treatment**

Dr. Ian Watson  
*Goodman Cancer Research Centre, McGill University*



12 h 45 à 13 h 15

LS 4B - Séance et discussion éclair – Oncologie gériatrique

<b>Identifying gaps in the care of older Albertans with cancer: Analysis of patient-reported, clinical, administrative, and survey datasets</b>	Dr. Fay Strohschein <i>University of Calgary</i>
<b>Prevalence of Preexisting Cognitive Impairment in Patients Treated for Cancer and Its Impact on Cognitive Outcomes</b>	Nelly Toledano <i>University of Toronto</i>
<b>Care Provided by Older Adult Caregivers to a Spouse in Active Cancer Treatment: A Scoping Review</b>	Mrs. Valentina Donison <i>University of Toronto</i>
<b>Comprehensive geriatric assessment and management for Canadian elders with Cancer: the 5C study</b>	Dr. Martine Puts <i>University of Toronto</i>
<b>Self-management interventions for issues identified in a geriatric assessment: a systematic review</b>	Mrs. Valentina Donison <i>University of Toronto</i>

13 h 15 à 13 h 30

Pause

13 h 30 à 14 h 30

ORAL 4C - Séance parallèle avec questions et réponses – Mobilisation des patients

Chairs:

Dr. David Dawe <i>CancerCare Manitoba, University of Manitoba</i>	Ms. Michelle Stratton <i>Patient Partner</i>	
<b>The top ten research priorities for early stage colorectal cancer: A Canadian patient oriented priority setting partnership</b>	Dr. Colleen Cuthbert <i>University of Calgary</i>	
<b>Real-world implementation of an electronic patient-reported outcomes program in cancer centres in Quebec (e-IMPAQc): successes, challenges, and lessons learned</b>	Dr. Sylvie Lambert <i>McGill University</i>	
<b>Operationalizing Patient Identified Priorities in the Breast Cancer Community</b>	Ms. Diana Ermel and Ms. Jenn Gordon <i>Canadian Breast Cancer Network</i>	

ORAL 4D - Séance parallèle avec questions et réponses – Bio-informatique et intelligence artificielle (IA)

Chairs:

Dr. Franco Vizeacoumar <i>Saskatchewan Cancer Agency, University of Saskatchewan</i>	Ms. Kirsten Efremov <i>Patient Partner</i>	Dr. Benjamin Haibe-Kains <i>University Health Network</i>
<b>Meta-analysis of preclinical pharmacogenomics studies for biomarker discovery</b>		



**Evolution of large copy number variants in breast cancer through genetic network rewiring**

Dr. Elena Kuzmin  
*McGill University*

**Multi-omic classification and characterization of pancreatic neuroendocrine neoplasms**

Dr. Sharon Gorski  
*BC Cancer*

### 13 h 30 à 14 h

#### LS 4C - Séance et discussion éclair – Prévention

**Mental Health Disorders, Cancer Risk, and the Mediating Role of Health Behaviours in the CARTaGENE Cohort Study**

Miss Kaitlyn Gilham  
*The University of British Columbia*

**A population-based study of salpingectomy and risk of epithelial ovarian cancer in Ontario**

Mr. Vasily Giannakeas  
*Women's College Hospital*

**Long working hours and prostate cancer risk: results from a population-based case-control study**

Miss Charlotte Salmon  
*Institut national de la recherche scientifique - Centre Armand-Frappier Santé Biotechnologie*

**Synergistic effects of combined inflammatory cytokines IFN $\gamma$ , IL1 $\beta$ , TNF $\alpha$ , and TGF $\beta$ , on the proliferation and gene expression of breast cancer cells**

Mr. Jorge Alfonso Leon Machado  
*Université de Sherbrooke*

**Dietary antioxidant formulation reduces carcinogen-induced DNA damage in bronchial epithelial cells in vitro**

Dr. Jose Merlin Jayaraj  
*Dalhousie University*

### 14 h à 14 h 30

#### LS 4D - Séance et discussion éclair – Risque de cancer et prévention primaire

**Effets de pesticides agricoles sur le transcriptome de cellules cancéreuses**

Miss Nadia Côté  
*Université de Sherbrooke*

**Sleep duration and ovarian cancer risk**

Mrs. Flavie Marquis  
*Université de Montréal*

**Omega-3 fatty acids and inflammatory markers expression in normal breast tissue**

Dr. Kaoutar Ennour-Idrissi  
*Laval University*

**Quality of life for men at risk of prostate cancer: a descriptive analysis from a large Canadian cohort**

Ms. Roxane Tourigny  
*CHU de Québec, Université Laval*

**UVR on skin tissues induce the retrotransposon LINE-1 expression reactivation**

Miss Marine Lambert  
*Research Institute of MUHC*



The Canadian Cancer  
Research Conference

La conférence canadienne  
sur la recherche sur le cancer

14 h 30 à 14 h 45

Pause

14 h 45 à 16 h 15

Séance principale et table ronde – Comprendre et gérer les risques – La saga du cancer héréditaire

Moderators:

Dr. Jacque Simard

*Centre de recherche du CHU de Quebec,  
Université Laval*

Ms. Nathalie Baudais

*Patient and Family Representative*

**The cellular specificity of hereditary cancers syndromes: two short stories**

Dr. David Huntsman

*BC Cancer, University of British Columbia*

**The Saga of Hereditary Cancer 1987 to 2021**

Dr. Steven Narod

*Women's College Research Institute*

**Family Histories and Hereditary Cancer Services: minimizing the bottleneck and opening the bottle**

Dr. Nadine Caron

*University of Northern British Columbia*

16 h 15 à 16 h 30

Synthèse de la CCRC de 2021